AHS warns of potential public measles exposures at Calgary airport
Alberta Health Services is notifying the public of a person in the Calgary zone who has been in public settings while infectious.
The first exposure took place on Wednesday at the Calgary International Airport's domestic arrival gate A17 between 8:10 a.m. and 11 a.m.
The second exposure location took place on the same day at the airport's domestic departure gate C55, WestJet flight 630 from Calgary International Airport to Charlottetown Airport. The time period is approximately between 8:50 a.m. to 3 p.m.
Anyone who attended either location at these times who was born in or after 1970 and has less than two documented doses of measles-containing vaccine may be at risk of developing measles.
They are encouraged to self-monitor for symptoms and are strongly encouraged to review their immunization records.
Symptoms include a fever of 38.3 C or higher; cough, runny nose, and/or red eyes; and a rash that can form three to seven days after fever starts.
Complications from measles include ear infections, pneumonia, inflammation of the brain, premature delivery and rarely death.
People who are pregnant, less than five years old, or have weakened immune systems are at the highest risk of serious complications.
If measles symptoms develop, AHS advises individuals to stay home and call the measles hotline at 1-844-944-3434 before visiting any health-care facilities or providers.
Alberta measles cases surpass 1,000
How to find out if you need the measles vaccine
In Alberta, measles vaccinations are offered free of charge through Alberta's publicly funded immunization program. The recommended schedule for measles vaccinations is in two doses, the first at one year of age, with a second at 18 months.
Anyone who thinks they are exposed and is not protected against measles may be eligible for immunization to reduce their risk of infection.
The dose needs to be provided within 72 hours of exposure to prevent measles. Babies under one year of age, people with severely weakened immune systems and those who are pregnant may be able to receive immunoglobulin.
Anyone looking for more information can do so by call the measles hotline. Alternatively, anyone over the age of 14 can visit myhealth.alberta.ca.
The measles hotline connects anyone to a professional who can assist in accessing their immunization records, offer general information, provide advice for those experiencing symptoms and help book measles immunization appointments or locate a public health clinic offering immunizations.
Residents can also text 'Measles' to 88111 for information texted to their mobile devices.
More information about routine childhood immunizations can be found online by visiting ahs.ca/immunization. More information on the risks of measles and frequently asked questions can be found on MyHealthAlberta.
For the latest information on measles in Alberta, visit ahs.ca/measles.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
an hour ago
- New York Times
With Flu Shot Vote, Kennedy's Vaccine Skepticism Comes Full Circle
A decade before he became President Trump's health secretary, the environmental lawyer Robert F. Kennedy Jr. appeared on a talk show hosted by Dr. Mehmet Oz to promote his latest book, 'Thimerosal: Let the Science Speak.' The book, published in 2014, explored an obscure mercury-based preservative, thimerosal, that was removed from most vaccines, but not flu vaccines, more than two decades ago. Dr. Oz noted that the Centers for Disease Control and Prevention had deemed the vaccines that still contained thimerosal 'safe and effective' and said they did 'not present a public health risk.' Mr. Kennedy did not buy it. 'We found 500 peer-reviewed studies,' he insisted. 'Virtually every one of them said that thimerosal is a potent neurotoxin that should not be in vaccines.' On Thursday, the new members of the C.D.C.'s Advisory Committee on Immunization Practices, hand-selected by Mr. Kennedy after he fired all 17 members of the previous panel, decided it would longer recommend annual flu shots that contain it. Thimerosal's appearance on the committee's agenda in the first place shocked public health leaders, who have long considered the matter settled. But it was not a surprise to people who have followed Mr. Kennedy closely. Thimerosal started Mr. Kennedy down a path of questioning vaccine safety, and Thursday's vote was the culmination of a long personal journey. It offers a window into how, as secretary, he is pursuing his own passions and installing old allies in positions of influence. Want all of The Times? Subscribe.
Yahoo
5 hours ago
- Yahoo
AHS warns of potential public measles exposures at Calgary airport
Alberta Health Services is notifying the public of a person in the Calgary zone who has been in public settings while infectious. The first exposure took place on Wednesday at the Calgary International Airport's domestic arrival gate A17 between 8:10 a.m. and 11 a.m. The second exposure location took place on the same day at the airport's domestic departure gate C55, WestJet flight 630 from Calgary International Airport to Charlottetown Airport. The time period is approximately between 8:50 a.m. to 3 p.m. Anyone who attended either location at these times who was born in or after 1970 and has less than two documented doses of measles-containing vaccine may be at risk of developing measles. They are encouraged to self-monitor for symptoms and are strongly encouraged to review their immunization records. Symptoms include a fever of 38.3 C or higher; cough, runny nose, and/or red eyes; and a rash that can form three to seven days after fever starts. Complications from measles include ear infections, pneumonia, inflammation of the brain, premature delivery and rarely death. People who are pregnant, less than five years old, or have weakened immune systems are at the highest risk of serious complications. If measles symptoms develop, AHS advises individuals to stay home and call the measles hotline at 1-844-944-3434 before visiting any health-care facilities or providers. Alberta measles cases surpass 1,000 How to find out if you need the measles vaccine In Alberta, measles vaccinations are offered free of charge through Alberta's publicly funded immunization program. The recommended schedule for measles vaccinations is in two doses, the first at one year of age, with a second at 18 months. Anyone who thinks they are exposed and is not protected against measles may be eligible for immunization to reduce their risk of infection. The dose needs to be provided within 72 hours of exposure to prevent measles. Babies under one year of age, people with severely weakened immune systems and those who are pregnant may be able to receive immunoglobulin. Anyone looking for more information can do so by call the measles hotline. Alternatively, anyone over the age of 14 can visit The measles hotline connects anyone to a professional who can assist in accessing their immunization records, offer general information, provide advice for those experiencing symptoms and help book measles immunization appointments or locate a public health clinic offering immunizations. Residents can also text 'Measles' to 88111 for information texted to their mobile devices. More information about routine childhood immunizations can be found online by visiting More information on the risks of measles and frequently asked questions can be found on MyHealthAlberta. For the latest information on measles in Alberta, visit
Yahoo
6 hours ago
- Yahoo
Biocon Biologics Receives Health Canada Approval for Yesafili™ (aflibercept); First Global Launch Scheduled for July 2025
TORONTO, Ontario, Canada and BENGALURU, Karnataka, India, June 27, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for Yesafili™ (aflibercept), a biosimilar to Eylea® (aflibercept) injection, in vial and prefilled syringe presentations, 2 mg/0.05 mL on June 26, 2025. This approval paves the way for the launch of YESAFILI in Canada, scheduled for July 4, 2025. YESAFILI is the first biosimilar to EYLEA to be approved by Health Canada. YESAFILI is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of: Neovascular (wet) age-related macular degeneration (AMD) Visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO) Visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO) Diabetic macular edema (DME) Myopic choroidal neovascularization (myopic CNV) The approval is based on a comprehensive package of analytical, nonclinical, and clinical data, confirming that YESAFILI is highly similar with no clinically meaningful differences to EYLEA in terms of quality, safety, and efficacy. Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd., said: 'The approval of YESAFILI by Health Canada—the first biosimilar to EYLEA® in Canada—is a proud moment for Biocon Biologics. We are excited that in July, Canada will be the first country where we will launch YESAFILI, making it our 10th biosimilar to be commercialized worldwide. This milestone reflects our science-driven innovation, global commercialization strength, and continued commitment to expanding access to high-quality, affordable biologics for patients across the globe.' Ramy Ayad, Head of Canada at Biocon Biologics, stated: 'This is a significant achievement for Biocon Biologics in Canada. With the approval of YESAFILI, we are delivering on our promise to improve access to advanced biologic therapies. Canadian ophthalmologists and patients will soon have a high-quality, affordable biosimilar option for serious retinal diseases.' About YESAFILI™:The approval for YESAFILI (aflibercept) was based on a comprehensive package of analytical, nonclinical, and clinical data, which confirmed that YESAFILI is highly similar to EYLEA. In a Phase 3 INSIGHT Study, YESAFILI was compared with EYLEA in patients with Diabetic Macular Edema. This study demonstrated that there were no clinically meaningful differences between YESAFILI and EYLEA in terms of pharmacokinetics, safety, efficacy, and immunogenicity. Indications and Usage: Treatment with YESAFILI (aflibercept) is for intravitreal injection only. YESAFILI is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) Visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO) Visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO) Diabetic Macular Edema (DME) Myopic choroidal neovascularization (myopic CNV) Warnings and Precautions: YESAFILI is contraindicated in patients with ocular or periocular infection, active intraocular inflammation, and hypersensitivity to aflibercept, to any ingredient in the formulation or to any component of the container. Patients may experience temporary visual disturbances after an intravitreal injection with YESAFILI and the associated eye examinations. They should not drive or use machines until visual function has recovered sufficiently. Hypersensitivity reactions may manifest as rash, pruritus, urticaria, severe anaphylactic/ anaphylactoid reactions, or severe intraocular inflammation. Endophthalmitis, retinal detachment, retinal tear, retinal pigment epithelium tear, cataract including traumatic cataract, vitreous hemorrhage and hyphema, may occur following intravitreal injections. Retinal vasculitis and retinal occlusive vasculitis, typically in the presence of intraocular inflammation or treatment with other intravitreal agents. Increases in intraocular pressure have been observed within 60 minutes of an intravitreal injection Please refer to full Product Monograph for YESAFILI for more information. To report SUSPECTED ADVERSE REACTIONS, contact Biocon Biologics at 1-833-986-1468. YESAFILI is a trademark of a Biocon Biologics BIOLOGICS and the Biocon Biologics Logo are trademarks of Biocon Biologics Limited. All other trademarks are the property of their respective owners. About Biocon Biologics Limited: Biocon Biologics Limited, a subsidiary of Biocon Limited, is a unique, fully integrated, global biosimilars company committed to transforming healthcare and transforming lives. It is capitalizing on its 'lab to market' capabilities to serve over 5.8 million patients across 120+ countries by enabling affordable access to high quality biosimilars. The Company is leveraging cutting-edge science, innovative tech platforms, global scale manufacturing capabilities and world-class quality systems to lower costs of biological therapeutics while improving healthcare outcomes. Biocon Biologics has commercialized nine biosimilars from its portfolio which are addressing the patients' needs in key emerging markets and advanced markets like U.S., Europe, Australia, Canada, and Japan. It has a pipeline of 20 biosimilar assets across diabetology, oncology, immunology, ophthalmology, bone health and other non-communicable diseases. The Company has many 'firsts' to its credit in the biosimilars industry. As part of its environmental, social and governance (ESG) commitment, it is advancing the health of patients, people, and the planet to achieve key UN Sustainable Development Goals (SDGs). Website: Follow us on X (formerly Twitter): @BioconBiologics and LinkedIn: Biocon Biologics for company updates. For FY24 Integrated Annual Report of Biocon Biologics click here Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development. Website: Follow-us on X (formerly Twitter) @bioconlimited and LinkedIn: Biocon for company updates. Forward-Looking Statements: BioconThis press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects upon Biocon and its subsidiaries/ associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian and global biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither Biocon, nor our Directors, or any of our subsidiaries/associates assume any obligation to update any particular forward-looking statement contained in this release. For More Information: Biocon Biologics MEDIA INVESTORS Seema AhujaGlobal Head of Corporate Brand & Head of Communications – Emerging Markets +91 99723 Lance LongwellPublic Relations Lead – Advanced Markets +1 857 270 Saurabh PaliwalHead - Investor RelationsBiocon +91 95383 80801 CONTACT: Lance Longwell Biocon Biologics Ltd 857-270-4391
